Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to 12.46%.

  • Niagen Bioscience's EBITDA Margin rose 620.00% to 12.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.48%, marking a year-over-year increase of 1499.00%. This contributed to the annual value of 7.76% for FY2024, which is 1446.00% up from last year.
  • Per Niagen Bioscience's latest filing, its EBITDA Margin stood at 12.46% for Q3 2025, which was up 21.77% from 10.24% recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's EBITDA Margin ranged from a high of 24.42% in Q4 2024 and a low of -51.08% during Q3 2021.
  • Its 3-year average for EBITDA Margin is 3.44%, with a median of -0.79% in 2023.
  • Its EBITDA Margin has fluctuated over the past 5 years, first slumped by 2,149bps in 2021, then surged by 3,607bps in 2023.
  • Niagen Bioscience's EBITDA Margin (Quarterly) stood at -29.93% in 2021, then skyrocketed by 2,306bps to -6.88% in 2022, then soared by 608bps to -0.79% in 2023, then surged by 2,521bps to 24.42% in 2024, then soared by 620bps to 12.46% in 2025.
  • Its last three reported values are 12.46% in Q3 2025, 10.24% for Q2 2025, and 15.66% during Q1 2025.